Navigation Links
Bioheart Inc. to Participate in the 2009 World Stem Cell Summit on September 23rd
Date:9/10/2009

our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended June 30, 2009, March 31, 2009; June 30, 2008 and September 30, 2008.

    Contact:
    At the Company:
    Karl E. Groth, Ph.D., Chairman and Chief Executive Officer
    (954) 835-1500


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Bioheart, Inc. Announces Financial Results for First Quarter 2008
4. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
5. Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008
6. Bioheart, Inc. to Transfer to Nasdaq Capital Market
7. Bioheart, Inc., Added to Russell Microcap Index
8. Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer
9. Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
10. Bioheart, Inc., Announces Management Change
11. Bioheart, Inc. Announces Results of Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Shimadzu Scientific Instruments ... multipurpose UV-visible spectrophotometer. Offering wavelength scanning from 190 ... ideal for applications in a variety of industries, ... The user-friendly UV-1280 enables intuitive operation, while the ...
(Date:1/22/2015)... Cambridge Semantics, the leading provider of smart data solutions ... a record-breaking year across the board for the company. ... Platform and our Smart Data solutions, our customers were able ... led to record growth for the company in 2014,” said ...
(Date:1/22/2015)... Diego, California (PRWEB) January 22, 2015 ... Promotional Offer to their comprehensive portfolio of Eppendorf ... allows customers to purchase a Centrifuge 5424/5424 R and ... Bundle of either Eppendorf Research plus or Eppendorf Reference ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
Breaking Biology Technology:Shimadzu’s New Monitored Single-Beam UV-Vis Spectrophotometer Offers Comprehensive Measurement Options in a Compact Body 2Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... May 7 Dendreon Corporation (Nasdaq: DNDN ) today announced ... Bank of America and Merrill Lynch 2009 Health Care Conference, ... May 12, 2009, 9:20 a.m. ET, ... Tuesday, May 19, 2009, 4:35 p.m. ...
... Thursday, May 7, 2009 at 4:30 p.m. Eastern ... OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: ... results for the three months ended March 31, ... first quarter of 2009. , The following consolidated ...
... 6 Spectros Corporation (Portola Valley, CA) filed ... Scientific (NYSE: TMO ), alleging infringement ... 3300 product. Spectros invented and commercialized solid-state, broadband, ... and incorporated these into its flagship T-Stat product, ...
Cached Biology Technology:OncoGenex Reports First Quarter Financial Results 2OncoGenex Reports First Quarter Financial Results 3OncoGenex Reports First Quarter Financial Results 4OncoGenex Reports First Quarter Financial Results 5OncoGenex Reports First Quarter Financial Results 6Spectros Corporation Protects Its Cool White LED Spectroscopy Technology Against Alleged Infringement by Thermo Fisher Scientific 2
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)...  BellBrook Labs, a leader in high throughput screening ... a TR-FRET (time resolved Forster resonance energy transfer) ... high throughput screening assay for glycosyltransferases and other ... sensitive detection of hundreds of human and microbial ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Institute researcher Dr Matthew Call has been awarded ... Innovation (VESKI) Fellowship by the Victorian Government to ... and signalling. Dr Call,s research could signal ... treating immune diseases, using creative ,membrane mimic, technology ...
... born to mothers who are fed a diet supplemented with ... scientists at the Jean Mayer USDA Human Nutrition Research Center ... research in humans and mice suggests that B vitamins, particularly ... Using a mouse model of naturally occurring colorectal cancer, the ...
... Ariz. June 9, 2011 TGen Drug Development ... the rapid development of anti-cancer drugs and deliver them ... "The highest quality medical imaging provided by Imaging ... Dr. Stephen Gately, President of TD2, which assists drug ...
Cached Biology News:Structural biologist wins $150K for 'membrane mimic' technology 2B vitamins in mother's diet reduce colorectal cancer risk in offspring 2TGen Drug Development partners with Imaging Endpoints for comprehensive clinical trial services 2
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
Automated Cell Culture Flask...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
Cell Culture Flask, 75 cm, treated polystyrene...
Biology Products: